טוען...
MON-365 Immune Checkpoint Inhibitors: Endocrinopathies and Severe Electrolyte Abnormalities
Background: Immune Checkpoint Inhibitors (ICPi) are promising therapies for advanced malignancies, including melanoma, lung cancer, and renal cancer. However, their use can induce mechanism-based toxicities called as immune-related adverse events (irAE) that can potentially affect various organ tiss...
שמור ב:
| הוצא לאור ב: | J Endocr Soc |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Endocrine Society
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6550888/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-365 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|